87 related articles for article (PubMed ID: 27717015)
1. Regulatory B10 cells display an altered homoeostasis in acute graft-versus-host disease.
Chakupurakal G; Garcia-Marquez MA; Shimabukuro-Vornhagen A; Kluth S; Schlosser H; Theurich S; Scheid C; Hallek M; Holtick U; von Bergwelt-Baildon M
Eur J Haematol; 2017 Feb; 98(2):128-133. PubMed ID: 27717015
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Immunological effects in patients with steroid-refractory graft-versus-host disease following treatment with basiliximab, a CD25 monoclonal antibody.
Chakupurakal G; García-Márquez MA; Shimabukuro-Vornhagen A; Theurich S; Holtick U; Hallek M; Scheid C; von Bergwelt-Baildon M
Eur J Haematol; 2016 Aug; 97(2):121-7. PubMed ID: 26492560
[TBL] [Abstract][Full Text] [Related]
4. Immunological reconstitution and correlation of circulating serum inflammatory mediators/cytokines with the incidence of acute graft-versus-host disease during the first 100 days following unrelated umbilical cord blood transplantation.
Abu-Ghosh A; Goldman S; Slone V; van de Ven C; Suen Y; Murphy L; Sender L; Cairo M
Bone Marrow Transplant; 1999 Sep; 24(5):535-44. PubMed ID: 10482939
[TBL] [Abstract][Full Text] [Related]
5. The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease.
Dunbar EM; Buzzeo MP; Levine JB; Schold JD; Meier-Kriesche HU; Reddy V
Haematologica; 2008 Dec; 93(12):1852-8. PubMed ID: 18945751
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts.
Bleakley M; Heimfeld S; Loeb KR; Jones LA; Chaney C; Seropian S; Gooley TA; Sommermeyer F; Riddell SR; Shlomchik WD
J Clin Invest; 2015 Jul; 125(7):2677-89. PubMed ID: 26053664
[TBL] [Abstract][Full Text] [Related]
7. High frequency of CD4+ CD25- CD69+ T cells is correlated with a low risk of acute graft-versus-host disease in allotransplants.
Lu SY; Huang XJ; Liu KY; Liu DH; Xu LP
Clin Transplant; 2012; 26(2):E158-67. PubMed ID: 22507356
[TBL] [Abstract][Full Text] [Related]
8. National Institutes of Health-Defined Chronic Graft-vs.-Host Disease in Pediatric Hematopoietic Stem Cell Transplantation Patients Correlates With Parameters of Long-Term Immune Reconstitution.
Lawitschka A; Gueclue ED; Januszko A; Körmöczi U; Rottal A; Fritsch G; Bauer D; Peters C; Greinix HT; Pickl WF; Kuzmina Z
Front Immunol; 2019; 10():1879. PubMed ID: 31507582
[TBL] [Abstract][Full Text] [Related]
9. Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: a retrospective study including 148 patients.
Heining C; Spyridonidis A; Bernhardt E; Schulte-Mönting J; Behringer D; Grüllich C; Jakob A; Bertz H; Finke J
Bone Marrow Transplant; 2007 May; 39(10):613-22. PubMed ID: 17384658
[TBL] [Abstract][Full Text] [Related]
10. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
[TBL] [Abstract][Full Text] [Related]
11. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
Bhatia M; Militano O; Jin Z; Figurski M; Shaw L; Moore V; Morris E; Tallamy B; van deVen C; Ayello J; Baxter-Lowe L; Satwani P; George D; Bradley MB; Garvin J; Cairo MS
Biol Blood Marrow Transplant; 2010 Mar; 16(3):333-43. PubMed ID: 19835971
[TBL] [Abstract][Full Text] [Related]
12. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
[TBL] [Abstract][Full Text] [Related]
13. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.
Baron F; Labopin M; Niederwieser D; Vigouroux S; Cornelissen JJ; Malm C; Vindelov LL; Blaise D; Janssen JJ; Petersen E; Socié G; Nagler A; Rocha V; Mohty M
Leukemia; 2012 Dec; 26(12):2462-8. PubMed ID: 22699419
[TBL] [Abstract][Full Text] [Related]
14. Helper T-lymphocyte precursor frequency predicts the occurrence of graft-versus-host disease and disease relapse after allogeneic bone marrow transplantation from HLA-identical siblings.
Leung AY; Kwok J; Lie AK; Chen P; Chen FE; Liang R
Haematologica; 2001 Jun; 86(6):652-6. PubMed ID: 11418376
[TBL] [Abstract][Full Text] [Related]
15. Higher doses of CD34+ progenitors are associated with improved overall survival without increasing GVHD in reduced intensity conditioning allogeneic transplant recipients with clinically advanced disease.
Gómez-Almaguer D; Gómez-Peña Á; Jaime-Pérez JC; Gómez-Guijosa MÁ; Cantú-Rodríguez O; Gutiérrez-Aguirre H; Martínez-Cabriales SA; García-Rodríguez F; Olguín-Ramírez LA; Salazar-Riojas R; Méndez-Ramírez N
J Clin Apher; 2013 Oct; 28(5):349-55. PubMed ID: 23682006
[TBL] [Abstract][Full Text] [Related]
16. Low-dose alemtuzumab vs. standard policy for prevention of graft-versus-host disease in unrelated and related allogeneic stem cell transplantation-a matched pair analysis.
Busemann C; Neumann T; Schulze M; Klenner A; Thiele T; Greinacher A; Dölken G; Krüger WH
Ann Hematol; 2013 Jul; 92(7):945-52. PubMed ID: 23463451
[TBL] [Abstract][Full Text] [Related]
17. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources.
Rocha V; Wagner JE; Sobocinski KA; Klein JP; Zhang MJ; Horowitz MM; Gluckman E
N Engl J Med; 2000 Jun; 342(25):1846-54. PubMed ID: 10861319
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease.
Kulkarni S; Powles R; Sirohi B; Treleaven J; Saso R; Horton C; Atra A; Ortin M; Rudin C; Goyal S; Sankpal S; Meller S; Pinkerton CR; Mehta J; Singhal S
Bone Marrow Transplant; 2003 Jul; 32(2):165-70. PubMed ID: 12838281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
